In an orthotopic hepatocellular carcinoma mouse model the implant is initially sensitive to sorafenib, another TKI blocking the VEGF pathway signaling, only to develop resistance after 1 month when an invasive phenotype develops and cancer cells switch to co‐option of sinusoidal and portal‐tract vessels in association with upregulation of epithelial mesenchymal transition (EMT)‐associated genes.56 Here, VEGFA is linked to cancer.